Skip to content
FidoCure® logo

FidoCure®

FidoCure® is a YC Winter 2018 (W18) company. Based in Palo Alto, CA, USA; Remote. Team of 14.

  • Oncology

About FidoCure®

GPAgent's own fund-neutral profile, written from public information. Updated Oct 5, 2026.

Summary

FidoCure® brings precision oncology to veterinary medicine, giving veterinarians a genomic testing and targeted therapy platform for dogs diagnosed with cancer. It sequences a tumor to identify cancer-driving mutations, then recommends personalized therapeutic options, replacing the default of standard chemotherapy or radiation with treatments matched to each dog's genetic profile.

Go-to-market

Veterinarians and veterinary oncologists are the direct customers, reached through a growing clinic network across the US. Practices join the FidoCure® network and order genomic tests on behalf of pet-owner clients.

From the Y Combinator listing

How FidoCure® describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

FidoCure® is the leader in Precision Medicine for Canine Oncology.

Cancer is a genetic disease. We know this from decades of human and veterinary cancer research. Precision medicine and targeted therapies are successfully used to treat humans with cancer. At FidoCure®, we bring this approach to the world of veterinary medicine. FidoCure® empowers veterinarians to offer genetic sequencing and targeted therapies to treat dogs with cancer. We are committed to expanding the veterinary oncology toolbox for both diagnostics and therapeutics. Our veterinary partners have treated thousands of dogs over the past 30 years and work closely with the growing FidoCure® network of over 143 clinics and 180 forward-thinking veterinary oncologists throughout the US. Together, we can combat canine cancer!

Facts

Industry
Healthcare / Healthcare -> Healthcare Services
Location
Palo Alto, CA, USA; Remote
Team size
14
Status
Active
Stage
Growth

Founders (1)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works